MiNK Therapeutics INKT
NASDAQ INKT
$12.55 +0.29 (+2.36%)
As of: Sep 30, 2026 · 3:55 PM EDT

MiNK Therapeutics (INKT) Convertible Debt (2020)

Updated

MiNK Therapeutics (INKT) posted Convertible Debt of $43.82 million for Q4 2020.

Analysis

MiNK Therapeutics (INKT) Convertible Debt (2020) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn
10 MiNK Therapeutics 62.49 Mn 62.49 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2020 43.82 Mn
API Access

MiNK Therapeutics Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=INKT&period=max&api_key=YOUR_API_KEY